Axsome Therapeutics, Inc.
Description
Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. It is also developing AXS-05, which is in Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-07, an investigational medicine that has completed Phase III trials for the acute treatment of migraine; AXS-12, an investigational medicine, which is in Phase III trial to treat narcolepsy; AXS-14, a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and solriamfetol, a dual-acting dopamine and norepinephrine reuptake inhibitor, which has completed a Phase 2 trial for treating attention-deficit/hyperactivity disorder, and is in phase 2 major depressive, binge eating, and shift work disorder. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.
About
CEO
Dr. Herriot Tabuteau M.D.
Employees
607
Instrument type
Common Stock
Sector
Healthcare
Industry
Biotechnology
MIC code
XNMS
Address
One World Trade Center, New York, NY 10007, United States
×
![Enlarged Chart]()
Oscillators
Invalid data format
Summary
Invalid data format
Moving Averages
Invalid data format
Earnings
| Date | Estimate EPS | Actual EPS | Difference | % Surprise |
|---|---|---|---|---|
| Nov 10, 2025 | — | — | — | — |
| Aug 4, 2025 | — | — | — | — |
| May 5, 2025 | — | — | — | — |
| Feb 18, 2025 | — | — | — | — |
| Nov 12, 2024 | -1.41 | -1.34 | 0.07 | -4.96% |
Earnings estimate
|
Next Quarter
(Mar 2025)
|
Next Year
(Dec 2025)
|
|||
|---|---|---|---|---|
| Number of analysts | — | 6 | — | 11 |
| Average estimate | — | -1.07 | — | -1.75 |
| Low estimate | — | -1.30 | — | -4.30 |
| High estimate | — | -0.81 | — | 2.99 |
| Last year EPS | — | -1.44 | — | -5.27 |
[stock_revenue_estimate]
Growth estimates
Current qtr
50.530%
Next qtr. (Mar 2025)
26.590%
Current year
0.360%
Next year (Dec 2025)
65.830%
Next 5 years (per annum)
—
Past 5 years (per annum)
—
Income statement
| 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|
| Fiscal date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Total reported revenue | 270.60M | 50.04M | — | — | — |
| Cost of revenue | 26.07M | 5.20M | — | — | — |
| Gross profit | 244.54M | 44.84M | — | — | — |
| Operating expense | |||||
| Research & development | 97.94M | 57.95M | 58.06M | 70.24M | 53.65M |
| Selling general and admin | 323.12M | 159.25M | 66.65M | 28.90M | 13.60M |
| Other operating expenses | — | — | — | — | — |
| Operating income | -182.91M | -176.50M | -124.71M | -99.09M | -67.11M |
| Non operating interest income | |||||
| Income | — | — | — | — | — |
| Expense | 6.45M | 7.34M | 5.70M | 2.57M | 1.24M |
| Other income expense | -48.92M | -3.30M | — | -1.25M | 139,448 |
| Pretax income | -238.28M | -187.13M | -130.40M | -102.90M | -68.35M |
| Tax provision | 960,000 | — | — | — | — |
| Net income | -239.24M | -187.13M | -130.40M | -102.90M | -68.35M |
| Basic EPS | -5.27 | -4.60 | -3.47 | -2.77 | -2.01 |
| Diluted EPS | -5.27 | -4.60 | -3.47 | -2.77 | -2.01 |
| Basic average shares | 45.43M | 40.66M | 37.62M | 37.21M | 34.02M |
| Diluted average shares | 45.43M | 40.66M | 37.62M | 37.21M | 34.02M |
| EBITDA | -176.07M | -172.10M | -124.63M | -99.01M | -67.07M |
| Net income from continuing op. | -239.24M | -187.13M | -130.40M | -102.90M | -68.35M |
| Minority interests | — | — | — | — | — |
| Preferred stock dividends | — | — | — | — | — |
Balance sheet
| 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|
| Fiscal date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Total assets | 588.24M | 331.48M | 87.79M | 186.13M | 220.55M |
| Current assets | |||||
| Cash | — | — | 86.47M | 183.88M | 219.97M |
| Cash equivalents | — | — | — | — | — |
| Cash and cash equivalents | 386.19M | 200.84M | 86.47M | 183.88M | 219.97M |
| Other short term investments | — | — | — | — | — |
| Accounts receivable | 94.82M | 37.70M | — | — | — |
| Other receivables | — | — | — | — | — |
| Inventory | 15.14M | 4.32M | — | — | — |
| Prepaid assets | — | — | 45,286 | 148,373 | 413,095 |
| Restricted cash | — | — | — | — | — |
| Assets held for sale | — | — | — | — | — |
| Hedging assets | — | — | — | — | — |
| Other current assets | 8.12M | 2.78M | 45,286 | 148,373 | 413,095 |
| Non current assets | |||||
| Properties | 846,000 | 722,000 | 283,846 | 52,647 | 30,623 |
| Land and improvements | — | — | — | — | — |
| Machinery furniture equipment | — | — | — | 52,647 | 30,623 |
| Construction in progress | — | — | — | — | — |
| Leases | — | — | — | 1.74M | — |
| Accumulated depreciation | — | — | — | — | — |
| Goodwill | 77.37M | 80.28M | — | — | — |
| Investment properties | — | — | — | — | — |
| Financial assets | — | — | — | — | — |
| Intangible assets | 53.29M | 59.66M | — | — | — |
| Investments and advances | — | — | — | — | — |
| Other non current assets | 11.03M | 14.72M | 322,910 | 317,375 | 139,875 |
| Total liabilities | 397.26M | 221.92M | 72.15M | 72.34M | 41.83M |
| Current liabilities | |||||
| Accounts payable | 40.68M | 38.61M | 13.15M | 13.50M | 10.94M |
| Accrued expenses | 70.04M | 40.35M | 5.24M | 5.84M | 8.89M |
| Short term debt | 1.27M | 425,000 | 620,675 | 1.22M | 2.60M |
| Deferred revenue | — | — | — | — | — |
| Tax payable | — | — | — | — | — |
| Pensions | 20.46M | 11.28M | 4.05M | 2.87M | 2.06M |
| Other current liabilities | 6.41M | 5.90M | — | — | 683,178 |
| Non current liabilities | |||||
| Long term debt | 185.11M | 94.26M | 49.09M | 48.90M | 17.33M |
| Provision for risks and charges | — | — | — | — | — |
| Deferred liabilities | — | — | — | — | — |
| Derivative product liabilities | — | — | — | — | — |
| Other non current liabilities | 73.30M | 31.10M | — | — | — |
| Shareholders equity | |||||
| Common stock | 5,000 | 4,000 | 3,782 | 3,737 | 3,693 |
| Retained earnings | -835.57M | -596.33M | -409.20M | -278.80M | -175.90M |
| Other shareholders equity | — | — | — | — | — |
| Total shareholders equity | 190.98M | 109.56M | 15.63M | 113.79M | 178.72M |
| Additional paid in capital | 1.03B | 705.89M | 424.83M | 392.59M | 354.61M |
| Treasury stock | — | — | — | — | — |
| Minority interest | — | — | — | — | — |
Cash flow statement
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | |||||||||||
| Net Income | -239.24M | -187.13M | -130.40M | -102.90M | -68.35M | -30.97M | -28.94M | -27.20M | -12.21M | -6.00M | -2.17M |
| Depreciation | 6.83M | 4.40M | 76,000 | 77,718 | 37,330 | 48,935 | 42,557 | 20,484 | 3,542 | — | — |
| Deferred Taxes | — | — | — | — | — | — | — | — | — | — | — |
| Stock-Based Compensation | 62.62M | 37.73M | 20.80M | 14.76M | 6.12M | 1.75M | 2.07M | 2.03M | 803,279 | 376,806 | 55,281 |
| Other Non-Cash Items | 53.10M | 4.83M | 974,000 | 7.95M | 649,993 | 375,635 | 470,521 | 68,930 | 748,785 | -2.23M | 327,192 |
| Accounts Receivable | -57.12M | -37.70M | — | — | — | — | — | — | — | — | — |
| Accounts Payable | 2.07M | 25.46M | -355,000 | 2.56M | 7.26M | 251,789 | -645,717 | 2.19M | 1.13M | 598,836 | 158,139 |
| Other Assets & Liabilities | -4.46M | -5.28M | -11,535 | -523,533 | -55,060 | 151,214 | -150,262 | -172,392 | -53,250 | — | — |
| Operating Cash Flow | -176.20M | -157.70M | -108.92M | -78.08M | -54.34M | -28.38M | -27.15M | -23.06M | -9.57M | -7.26M | -1.63M |
| Investing Activities | |||||||||||
| Capital Expenditures | -582,000 | -702,000 | -308,000 | -45,891 | -16,121 | -32,696 | -9,898 | -104,561 | -20,195 | — | — |
| Net Intangibles | — | — | — | — | — | — | — | — | — | — | — |
| Net Acquisitions | — | -53.00M | — | — | — | — | — | — | — | — | — |
| Purchase of Investments | — | — | — | — | — | — | — | — | — | — | — |
| Sale of Investments | — | — | — | — | — | — | — | — | — | — | — |
| Investing Cash Flow | -582,000 | -53.70M | -308,000 | -45,891 | -16,121 | -32,696 | -9,898 | -104,561 | -20,195 | — | — |
| Financing Activities | |||||||||||
| Long-Term Debt Issuance | 85.00M | 45.00M | — | 50.00M | 20.00M | — | — | 10.00M | 7.38M | 5.21M | 3.78M |
| Long-Term Debt Payments | — | — | — | -21.66M | -7.24M | -3.33M | -277,778 | — | -41,469 | -21,000 | — |
| Other Financing Charges | -25.16M | -10.43M | -708,000 | -1.10M | — | -25,997 | — | -64,928 | -12,489 | -62,520 | -57,983 |
| Financing Cash Flow | 318.59M | 278.33M | 6.73M | 41.36M | 250.99M | 9.52M | 23.40M | 9.94M | 52.88M | 5.13M | 3.72M |
| Other Cash Details | |||||||||||
| End Cash Position | 386.19M | 200.84M | 86.47M | 183.88M | 219.97M | 13.97M | 34.02M | 36.62M | 48.04M | 2.62M | 2.09M |
| Income Tax Paid | — | — | — | — | — | — | — | — | — | — | — |
| Interest Paid | 16.73M | 7.69M | 4.63M | 2.10M | 1.29M | 771,966 | 865,278 | 46,667 | — | — | — |
| Free Cash Flow | -145.66M | -117.21M | -108.53M | -78.50M | -46.39M | -30.09M | -26.48M | -21.39M | -7.46M | -4.60M | -1.63M |
Top Institutional Holders
| Holder | Date Reported | Shares | Value | % Held |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | Sep 30, 2024 | 1,311,059 | 148.04M | 2.71% |
| iShares Russell 2000 ETF | Nov 30, 2024 | 1,021,203 | 115.31M | 2.11% |
| Vanguard Small-Cap Index Fund | Sep 30, 2024 | 1,020,976 | 115.29M | 2.11% |
| Vanguard Extended Market Index Fund | Sep 30, 2024 | 609,534 | 68.83M | 1.26% |
| Delaware Group Equity Fds V-Small Cap Core Fund | Nov 30, 2024 | 579,637 | 65.45M | 1.20% |
| Vanguard Small-Cap Growth Index Fund | Sep 30, 2024 | 563,226 | 63.60M | 1.16% |
| Mutual Fund Ser Tr-Eventide Gilead Fund | Sep 30, 2024 | 439,573 | 49.64M | 0.91% |
| Mutual Fund Ser Tr-Eventide Healthcare & Life Sciences Fund | Sep 30, 2024 | 386,327 | 43.62M | 0.80% |
| Fidelity Small Cap Index Fund | Oct 31, 2024 | 372,170 | 42.03M | 0.77% |
| Roxbury/Hood River Small Cap Growth Fund | Oct 31, 2024 | 365,168 | 41.23M | 0.75% |
Article
Axsome Gets FDA Nod for New Migraine Drug Symbravo, Stock Rises
The FDA approves AXSM's Symbravo for the acute treatment of migraine with or without aura in adults. The latest nod diversifies its commercial portfolio.
Jan 31, 2025
Article
Axsome Therapeutics Hosts SYMBRAVO® FDA Approval Virtual Investor Event with Expert Thought Leader
NEW YORK, Jan. 31, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, will host a virtual investor event and conference call today at 8:00 AM Eastern Time to discuss the U.S. Food and Drug Administration (FDA) approval of SYMBRAVO®, a novel multi-mechanistic approach to treating migraine that targets multiple pathways underlying a migraine attack.
Jan 31, 2025
Article
US FDA approves Axsome Therapeutics' migraine drug
The U.S. Food and Drug Administration has approved Axsome Therapeutics' migraine treatment, the company said on Thursday.
Jan 30, 2025
